1.2% Rosuvastatin and 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in the Treatment of Class II Furcation Defects: A Randomized Controlled Clinical Trial

Garg, Shruti; Pradeep, A.R.

doi:10.1902/jop.2016.160399

Cited by 25 publications

(75 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 14 studies were further excluded. After the final stage of selection, 11 studies were included and processed for data extraction (ĸ score for inter‐assessor agreement [95% CI: 0.91, 0.88‐0.94]) . All of the studies were performed at university hospitals.…”

Section: Resultsmentioning

confidence: 99%

“…All clinical studies were RCT . In all of the studies, the number of participants ranged between 38 and 90, with age ranging between 25 and 60 years.…”

Section: Resultsmentioning

confidence: 99%

“…The included studies used different definitions of CP . The PD threshold value for the inclusion of CP patients was PD ≥3 mm in one study, PD of ≥5 mm in eight studies, and PD of 5‐6 mm or ≥7 mm in two studies . In all of the studies, participants in the test group received statin delivery + SRP, while the control group used SRP with placebo gel.…”

Section: Resultsmentioning

confidence: 99%

“…In all of the studies, participants in the test group received statin delivery + SRP, while the control group used SRP with placebo gel. Six studies used atorvastatin (ATV), in which five used 1.2% local ATV application, while one used oral ATV (20 mg/day) . Four studies used 1.2% local simvastatin (SMV) gel, while three used 1.2% local rosuvastatin (RSV) gel as an adjunct to SRP for treatment of CP .…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of statin delivery as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A meta‐analysis

Akram

Vohra

Javed

2017

J of Invest & Clin Dent

View full text Add to dashboard Cite

The action of statins in stimulating bone formation and having other pleiotropic effects, such as anti-inflammatory and immunomodulatory effects, has justified their use as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis (CP). The aim of the present study was to evaluate the efficacy of statin delivery as an adjunct to SRP in the treatment of CP. Electronic searches were conducted using the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register, up until July 2017. The primary outcome was probing depth (PD), while the secondary outcomes were changes in clinical attachment level (CAL) and bone defect (BD) fill. Eleven studies were included, and all showed significant PD reduction, CAL gain, and BD fill with adjunctive statin delivery compared to SRP alone. The meta-analysis showed significant improvement in periodontal parameters for atorvastatin (PD: weighted mean difference [WMD] = -1.84, -2.56 to -1.12, P < .001; CAL: WMD = -2.31, -3.58 to -1.03, P < .001; BD fill: WMD = 2.66, -3.92 to -1.39, P < .001), simvastatin (PD: WMD = -1.91, -2.27 to -1.55, P < .001; CAL: WMD = -1.91, -2.27 to -1.55, P = .001; BD: WMD = -1.52, -2.20 to -0.85, P < .001), and rosuvastatin (PD: WMD = -0.94, -1.32 to -0.55, P < .001; CAL: WMD = -1.00, -1.41 to -0.60, P < .001; BD fill: WMD = -1.30, -1.80 to -0.79, P < .001). Adjunctive statin delivery appears to be effective in reducing PD, CAL gain, and BD fill in CP, and therefore, these drugs could be a promising therapeutic option for periodontal regeneration in future.

show abstract

Section: Resultsmentioning

confidence: 99%

“…All clinical studies were RCT . In all of the studies, the number of participants ranged between 38 and 90, with age ranging between 25 and 60 years.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of statin delivery as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A meta‐analysis

Akram

Vohra

Javed

2017

J of Invest & Clin Dent

View full text Add to dashboard Cite

show abstract

“…Los sistemas incluyen: geles, fibras, películas, vesículas, micropartículas. Sin embargo, de acuerdo con lo revisado actualmente el sistema preferido para liberar y transportar estatinas es el gel 32,38,39 . Por tanto, esta revisión se centra especialmente en esos sistemas de liberación local.…”

Section: Estatinas En Sistemas De Liberación Localunclassified

Sistemas de administración de estatinas en el tratamiento de la periodontitis: una revisión de literatura

Gutiérrez¹,

Fernández

Pieschacón³

et al. 2019

View full text Add to dashboard Cite

La periodontitis es la inflamación de los tejidos periodontales que puede causar destrucción de los tejidos de soporte del diente, ocasionando pérdida ósea y dental. La periodontitis crónica es causada por bacterias periodontopatógenas como Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitams, Tannerella forsythia y Treponema dentícola, que activan el sistema inmune innato y adaptativo. El tratamiento de la enfermedad periodontal involucra estrategias no quirúrgicas como el raspaje y alisado radicular y tratamiento adjunto que incluye la administración de antibióticos sistémicos y locales como metronidazol, amoxicilina, tetraciclinas, además del uso de estatinas; fármacos utilizados principalmente contra la hiperlipidemia como la simvastatina. El uso de estatinas en la enfermedad periodontal, es dado por su efecto antiinflamatorio, además de estimular la formación ósea, la angiogénesis y su actividad antimicrobiana. Para la aplicación de estos fármacos en el tratamiento de la periodontitis crónica se han utilizado diferentes medios de administración, como: geles, fibras, películas, vesículas, y nanopartículas, destacándose el gel como el sistema preferido para liberar y transportar estatinas, el cual reduce los efectos adversos de la administración sistémica y son más efectivos para la cicatrización ósea. En periodoncia, las estatinas han mostrado una disminución en los parámetros clínicos periodontales después de 6 meses de tratamiento. Sin embargo, existen pocas revisiones temáticas que permitan a la comunidad académica reunir la información pertinente al respecto. Por lo anterior, se vio la necesidad de realizar una revisión de la literatura con el fin de describir los sistemas de administración local y sistémica de estatinas en el tratamiento de la periodontitis.

show abstract

Association between antihyperlipidemic agents and the risk of chronic periodontitis in patients with hyperlipidemia: A population‐based retrospective cohort study in Taiwan

Wang,

Lin,

Keller

et al. 2023

Journal of Periodontology

View full text Add to dashboard Cite

BackgroundThe lipid‐lowering and anti‐inflammatory effects of statins and fibrates may ameliorate periodontitis. Patients with hyperlipidemia tend to have a worse periodontal status. This study assessed the association between the use of statins/fibrates and the incidence of chronic periodontitis in patients with hyperlipidemia in Taiwan.MethodsThis retrospective cohort study enrolled patients newly diagnosed with hyperlipidemia between 2001 and 2012 from the 2000 Longitudinal Generation Tracking Database and followed them for 5 years. The study population was divided into four groups: statin monotherapy, fibrate monotherapy, combination therapy (both statins and fibrates), and control (neither statins nor fibrates). Each patient in the treatment group was matched at a ratio of 1:1 with a control. Chronic periodontitis risk was compared in the three study arms by using a Cox proportional hazard model.ResultsChronic periodontitis risk was reduced by 25.7% in the combination therapy group compared with the control group (adjusted hazard ratio [aHR], 0.743; 95% confidence interval (CI), 0.678–0.815). Low dose (<360 cumulative defined daily dose [cDDD]) and shorter duration (<2 years) of statin monotherapy seem to be associated with an increased risk of chronic periodontitis; high dose (≥720 cDDD/≥1080 cDDD) and longer duration (≥3 years) of statin/fibrate monotherapy may be correlated with a lower risk of periodontitis. Hydrophobic statin users had a lower chronic periodontitis risk than hydrophilic statin users.ConclusionChronic periodontitis risk was lower in patients with hyperlipidemia on combination treatment with statins and fibrates, and the risk decreased when patients used statins or fibrates for >3 years.

show abstract

1.2% Rosuvastatin and 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in the Treatment of Class II Furcation Defects: A Randomized Controlled Clinical Trial

Abstract: The RSV group shows significant improvement in all clinical parameters and significantly greater DDR compared with the ATV group in treatment of mandibular Class II furcation defects as an adjunct to SRP.

Cited by 25 publications

References 40 publications

Efficacy of statin delivery as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A meta‐analysis

Efficacy of statin delivery as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A meta‐analysis

Sistemas de administración de estatinas en el tratamiento de la periodontitis: una revisión de literatura

Association between antihyperlipidemic agents and the risk of chronic periodontitis in patients with hyperlipidemia: A population‐based retrospective cohort study in Taiwan

Contact Info

Product

Resources

About